Provided by Tiger Trade Technology Pte. Ltd.

ALPHAMAB-B

7.540
-0.545-6.74%
Volume:1.39M
Turnover:10.67M
Market Cap:7.29B
PE:-62.83
High:8.055
Open:8.055
Low:7.500
Close:8.085
52wk High:15.750
52wk Low:6.230
Shares:967.00M
HK Float Shares:967.00M
Volume Ratio:2.56
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.120
ROE:-9.98%
ROA:-5.47%
PB:3.72
PE(LYR):-62.83
PS:12.02

Loading ...

ALPHAMAB-B's Novel Drug Application for Anniutuo (KN026) in HER2-Positive Breast Cancer Neoadjuvant Therapy Accepted by Chinese Regulator

Stock News
·
Aug 04

Alphamab Oncology receives NMPA priority review for Anbenitamab NDA in neoadjuvant HER2+ breast-cancer therapy

Bulletin Express
·
Aug 04

Alphamab Oncology Says NMPA Accepts NDA for Anbenitamab (kn026)

Reuters
·
Aug 04

Alphamab Oncology - Nmpa Accepts Nda for Anbenitamab (Kn026) as Neoadjuvant Her2+ Breast Cancer Treatment

THOMSON REUTERS
·
Aug 04

HK-Listed Alphamab Hits 2-Month High on Breast Cancer Drug Licensing Deal

Reuters
·
Aug 04

ALPHAMAB-B Surges Over 12% in Morning Trade Following $2.1 Billion TROP2/HER3 Dual Antibody ADC Export Licensing Deal

Deep News
·
Aug 04

Alphamab Oncology - Jiangsu Alphamab to Receive $125 Mln Upfront, up to $2.09 Bln Total from Pathos AI

THOMSON REUTERS
·
Aug 04

Alphamab Oncology - Unit Granted Pathos AI Exclusive License to Commercialize Jskn016 in Territories Outside Chinese Mainland, HK, Macau, Taiwan

THOMSON REUTERS
·
Aug 04

Alphamab Oncology Licenses Jskn016 Ex-China Rights to Pathos AI for up to USD 2.09 Billion

Reuters
·
Aug 04

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on Jskn016, a First-in-Class Trop2/Her3 Bispecific ADC

THOMSON REUTERS
·
Aug 04

Alphamab Oncology Announces Approval from CDE for Jskn033 to Initiate a Phase III Clinical Study

Reuters
·
Aug 04

ALPHAMAB-B wins CDE green light to start Phase III trial of subcutaneous bispecific ADC/PD-L1 combo JSKN033 for hard-to-treat cervical cancer

Bulletin Express
·
Aug 03

Alphamab Oncology - Approval from Cde for Jskn033 to Initiate a Phase Iii Clinical Study for Treatment of Cervical Cancer

THOMSON REUTERS
·
Aug 03

Alphamab Oncology Says China CDE Clears Jskn033 Phase 3 Trial in Recurrent or Metastatic Cervical Cancer

Reuters
·
Aug 03

Alphamab-B Shares Surge 10% on Breakthrough Therapy Designation for Breast Cancer Treatment

Stock News
·
Jul 15

Alphamab Oncology Says China Regulator Grants Breakthrough Tag for Anbenitamab in First-line HER2+ Advanced Breast Cancer

Reuters
·
Jul 14

Alphamab Oncology - Anbenitamab (kn026) Granted Breakthrough Therapy Designation by Nmpa for Her2+ Breast Cancer

THOMSON REUTERS
·
Jul 14

Hang Seng Tech Index Extends Losses to 2%, Knowledge Atlas and Baidu Lead Declines

Deep News
·
Jul 14

ALPHAMAB-B pares 0.02% of outstanding shares in June amid HKD1.11 million buy-back

Bulletin Express
·
Jul 07

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23